Lv31
310 积分 2024-06-13 加入
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
30分钟前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
33分钟前
已完结
Usage des progestatifs et risque de méningiome intracrânien - Nouvelles données et enjeux cliniques [Use of progestogens and risk of intracranial meningioma: new data and clinical challenges]
4个月前
已关闭
Orforglipron in type 2 diabetes mellitus and obesity: an overview
5个月前
已完结
Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy
1年前
已关闭
Early pregnancy assessment units
1年前
已关闭
皖公网安备34019202002308
